NEW DELHI: Glenmark Life Sciences' initial public offering (IPO) was subscribed 44.17 times over the 1.50 crore shares that were on offer during the subscription period from July 27-29, 2021. The price band was fixed at Rs 695-720 per share.
The company is a wholly-owned subsidiary of Glenmark Pharmaceuticals.
The initial offer received bids of 66,33,24,160 shares against the total issue size of 1,50,18,279 shares, data available with the National Stock Exchange (NSE) showed.
The shares which are to be allocated for the qualified institutional buyers (QIBs) was subscribed 36.97 times, while those of non institutional investors was subscribed a whopping 122.54 times and that of retail individual investors (RIIs) was subscribed 14.63 times, the data showed.
The IPO of Glenmark Life Sciences has a total size of Rs 1,513.6 crore comprising of a fresh issue of equity shares worth Rs 1,060 crore and an offer for sale (OFS) comprising of up to 63 lakh equity shares worth Rs 453.6 crore by Glenmark Pharma.
The company is a leading developer and manufacturer of select high value, non-commoditised active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management and diabetes.
It also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas.
If you have applied for the IPO, then here's how you can check the allotment status:
* Visit KFin Technologies' -- registrar of the IPO -- website.
* Select 'GLENMARK LIFE SCIENCES LIMITED' in the drop-down menu and enter either their Application No. or DPID/Client ID or PAN.
* Enter the Captcha code and click on Submit.
* Via BSE website.
* Select 'GLENMARK LIFE SCIENCES LIMITED' from the drop-down list in the Issue Name section.
* Enter Application Number and PAN Number and click on search.
(With inputs from agencies)
